Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > COLUMN
COLUMN
-
Maurer's Healthcare Insight (124)
October 11, 2010
-
Maurer's Healthcare Insight (123)
July 12, 2010
-
Maurer's Healthcare Insight (122)
May 31, 2010
-
Maurer's Healthcare Insight (121)
May 3, 2010
-
Maurer's Healthcare Insight (120)
April 12, 2010
-
Maurer's Healthcare Insight (119)
March 1, 2010
-
Maurer's Healthcare Insight (118)
January 4, 2010
-
Maurer's Healthcare Insight (117)
December 14, 2009
-
Maurer's Healthcare Insight (116)
November 30, 2009
-
Maurer's Healthcare Insight (115)
November 16, 2009
-
Maurer's Healthcare Insight (114)
October 26, 2009
-
Maurer's Healthcare Insight (113)
October 5, 2009
-
Maurer's Healthcare Insight (112)
September 14, 2009
-
Maurer's Healthcare Insight (111)
August 24, 2009
-
Maurer's Healthcare Insight (110)
July 27, 2009
-
Maurer's Healthcare Insight (109)
June 22, 2009
-
Maurer's Healthcare Insight (108)
May 18, 2009
-
Maurer's Healthcare Insight (107)
April 27, 2009
-
Maurer's Healthcare Insight (106)
March 30, 2009
-
Maurer's Healthcare Insight (105)
March 2, 2009
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…